Hematology and Stem Cell Transplantation Unit, IRCCS Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy.
Division of Hematology, AOU Città della Salute e della Scienza di Torino, University of Torino, Torino, Italy.
Eur J Haematol. 2017 Oct;99(4):306-314. doi: 10.1111/ejh.12918. Epub 2017 Aug 3.
To evaluate the prognostic significance of oxidative stress (OS) and antioxidant defence status measurement in patients with chronic lymphocytic leukaemia (CLL).
d-ROMs test and BAP test were evaluated at diagnosis of 165 patients with CLL and correlated with clinical-biological features and prognosis.
An increased oxidative damage (d-ROMs test) and a reduced antioxidant potential (BAP test) were found in CLL patients than normal controls (P<.0001). CLL patients with higher d-ROMs values had higher number of circulating white blood cells and lymphocytes, and higher values of β -microglobulin. Higher d-ROMs values were found in female (P=.0003), in patients with unmutated IgVH (P=.04), unfavourable cytogenetics (P=.002) and more advanced clinical stage (P=.002). Higher BAP test values were found in patients expressing CD49d (P=.01) and with more advanced clinical stage (P=.004). At a median follow-up of 48 months, CLL patients with d-ROMs ≥418 CARR U were found to have a shorter time to first treatment (TFT) (P=.0002), and a reduced survival (P=.006) than others. CLL patients with BAP test values ≥2155 μmol/L had a shorter TFT (P=.008) and a shorter survival (P=.003).
OS can affect CLL patients by concomitantly increasing reactive oxygen metabolites production and decreasing antioxidant defences.
评估慢性淋巴细胞白血病（CLL）患者氧化应激（OS）和抗氧化防御状态测量的预后意义。
在 165 例 CLL 患者诊断时评估 d-ROMs 试验和 BAP 试验，并将其与临床生物学特征和预后相关联。
与正常对照组相比，CLL 患者的氧化损伤（d-ROMs 试验）增加，抗氧化能力降低（BAP 试验）（P<.0001）。d-ROMs 值较高的 CLL 患者循环白细胞和淋巴细胞数量较多，β-微球蛋白值较高。d-ROMs 值较高的患者为女性（P=.0003）、免疫球蛋白重链可变区（IgVH）未突变（P=.04）、不良细胞遗传学（P=.002）和更晚期的临床分期（P=.002）。表达 CD49d 的患者（P=.01）和更晚期的临床分期（P=.004）的患者的 BAP 试验值较高。在中位随访 48 个月时，d-ROMs≥418 CARR U 的 CLL 患者首次治疗（TFT）时间更短（P=.0002），生存时间更短（P=.006）。BAP 试验值≥2155 μmol/L 的 CLL 患者 TFT 更短（P=.008），生存时间更短（P=.003）。
OS 可通过同时增加活性氧代谢物的产生和降低抗氧化防御来影响 CLL 患者。
